Who are Tegafur-Ugotex or Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Capecitabine tablets, Phthalin, 5Fluorouracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tegafur-ugotex-or-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tegafur-Ugotex or Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tegafur-Ugotex or Capecitabine (Tegafur-Ugotex or Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; 5-fluorouracil prodrug. Area: Oncology.

marketed Antimetabolite; 5-fluorouracil prodrug Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tegafur-Ugotex or Capecitabine (Tegafur-Ugotex or Capecitabine) — Liaoning Cancer Hospital & Institute. Tegafur-Uracil (Tegafur-Ugotex) is a combination prodrug that inhibits thymidylate synthase to block DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tegafur-Ugotex or Capecitabine TARGET	Tegafur-Ugotex or Capecitabine	Liaoning Cancer Hospital & Institute	marketed	Antimetabolite; 5-fluorouracil prodrug	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Capecitabine tablets	Capecitabine tablets	UNICANCER	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Phthalin	PHENOLPHTHALEIN		marketed	phenolphthalein	Thymidylate synthase, Thymidylate synthase
5Fluorouracil	5Fluorouracil	University of Nebraska	marketed	Antimetabolite	Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; 5-fluorouracil prodrug class)

Liaoning Cancer Hospital & Institute · 1 drug in this class
Yokohama City University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tegafur-Ugotex or Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/tegafur-ugotex-or-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab